Valuation Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
03:53:31 05/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 55.43 USD | -0.91% |
|
-4.06% | +25.89% |
| 08-22 | Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says | MT |
| 08-22 | Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating | MT |
Company Valuation: Scholar Rock Holding Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 872.1 | 467.6 | 1,356 | 4,046 | 4,493 | 6,813 | - | - |
| Change | - | -46.39% | 190.08% | 198.32% | 11.06% | 51.61% | - | - |
| Enterprise Value (EV) 1 | 709.3 | 414 | 1,304 | 3,918 | 4,270 | 6,496 | 6,408 | 6,443 |
| Change | - | -41.63% | 215.07% | 200.38% | 8.97% | 52.13% | -1.35% | 0.55% |
| P/E | -6.92x | -4x | -9.45x | -17.5x | -13.4x | -17.2x | -21.8x | -36.3x |
| PBR | 5.3x | 2.07x | 6.96x | 11x | 20.6x | 25.7x | 23x | 25.4x |
| PEG | - | 0.1x | 0.8x | -0.7x | -0.4x | 13.46x | 1x | 0.9x |
| Capitalization / Revenue | 46.3x | 14.1x | - | - | - | 1,199x | 46.6x | 19.5x |
| EV / Revenue | 37.7x | 12.5x | - | - | - | 1,143x | 43.8x | 18.5x |
| EV / EBITDA | -5.57x | - | - | - | -11.1x | -15.1x | -21.7x | -66.8x |
| EV / EBIT | -5.46x | -3.08x | -7.62x | -15.5x | -11.1x | -14.8x | -18.4x | -33.5x |
| EV / FCF | -5.37x | -3.1x | -8.98x | -19.5x | -14.2x | -19.4x | -29.4x | -81.6x |
| FCF Yield | -18.6% | -32.3% | -11.1% | -5.13% | -7.04% | -5.16% | -3.4% | -1.23% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.59 | -2.26 | -1.99 | -2.47 | -3.29 | -3.248 | -2.572 | -1.542 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 18.82 | 33.19 | - | - | - | 5.684 | 146.1 | 348.8 |
| EBITDA 1 | -127.3 | - | - | - | -383 | -429 | -295.2 | -96.48 |
| EBIT 1 | -129.9 | -134.4 | -171.3 | -252.1 | -384.6 | -437.7 | -348.9 | -192.3 |
| Net income 1 | -131.8 | -134.5 | -165.8 | -246.3 | -377.9 | -425.3 | -363.8 | -213.1 |
| Net Debt 1 | -162.8 | -53.53 | -51.84 | -127.7 | -223.8 | -317.2 | -404.9 | -369.9 |
| Reference price 2 | 24.84 | 9.05 | 18.80 | 43.22 | 44.05 | 55.94 | 55.94 | 55.94 |
| Nbr of stocks (in thousands) | 35,108 | 51,663 | 72,143 | 93,615 | 102,007 | 121,785 | - | - |
| Announcement Date | 7/3/22 | 7/3/23 | 19/3/24 | 27/2/25 | 3/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -17.22x | 1142.75x | -15.14x | -.--% | 6.81B | |
| 20.62x | 7.16x | 14.45x | 1.43% | 69.02B | |
| 37.68x | 9.86x | 30.11x | 0.04% | 66.32B | |
| -77.54x | 14.97x | -72.18x | -.--% | 27.66B | |
| -15.71x | 6.02x | -7.56x | -.--% | 25.84B | |
| 30.64x | 6.56x | 17.04x | -.--% | 26.54B | |
| 27.79x | 5.19x | 17.27x | -.--% | 20.4B | |
| 50.92x | 18.81x | 38.16x | 0.3% | 17.63B | |
| 1308.71x | 37.87x | 826.39x | -.--% | 15.15B | |
| 18.26x | 5.45x | 12.72x | -.--% | 14.65B | |
| Average | 138.41x | 125.46x | 86.13x | 0.18% | 29B | |
| Weighted average by Cap. | 81.44x | 37.13x | 51.30x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SRRK Stock
- Valuation Scholar Rock Holding Corporation
Select your edition
All financial news and data tailored to specific country editions
